Cargando…
Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis
BACKGROUND: Sorafenib might prevent hepatocellular carcinoma (HCC) recurrence caused by the promotion of neoangiogenesis after transarterial chemoembolization (TACE). OBJECTIVES: To evaluate the efficacy and safety of TACE followed by sorafenib for treating advanced HCC. PATIENTS AND METHODS: We ret...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621710/ https://www.ncbi.nlm.nih.gov/pubmed/26446004 http://dx.doi.org/10.1007/s40261-015-0333-3 |
_version_ | 1782397484810633216 |
---|---|
author | Ohki, Takamasa Sato, Koki Yamagami, Mari Ito, Daisaku Yamada, Tomoharu Kawanishi, Koki Kojima, Kentaro Seki, Michiharu Toda, Nobuo Tagawa, Kazumi |
author_facet | Ohki, Takamasa Sato, Koki Yamagami, Mari Ito, Daisaku Yamada, Tomoharu Kawanishi, Koki Kojima, Kentaro Seki, Michiharu Toda, Nobuo Tagawa, Kazumi |
author_sort | Ohki, Takamasa |
collection | PubMed |
description | BACKGROUND: Sorafenib might prevent hepatocellular carcinoma (HCC) recurrence caused by the promotion of neoangiogenesis after transarterial chemoembolization (TACE). OBJECTIVES: To evaluate the efficacy and safety of TACE followed by sorafenib for treating advanced HCC. PATIENTS AND METHODS: We retrospectively analyzed 95 advanced HCC patients treated with TACE between July 2008 and December 2012 at our institution. Twenty-four patients received TACE followed by sorafenib within 14 days (S-TACE) and 71 received TACE alone. Progression-free survival (PFS) and cumulative survival from the time of non-responsiveness to TACE were compared between groups and predictive factors for PFS were analyzed. RESULTS: The median patient age was 72.2 years and 74 patients were male (77.9 %). Although median tumor size was similar between groups, the mean tumor number was significantly higher in the S-TACE versus TACE-alone group (16 vs. 8, P = 0.04). The number of prior treatments was significantly higher in the S-TACE group. Other baseline variables were similar. There were two severe adverse events in the S-TACE group and none in the TACE-alone group. Median PFS (189 vs. 106 days, P = 0.02) and median overall survival time (861 vs. 467 days, P = 0.01) from the time of non-responsiveness to TACE were significantly longer with S-TACE than TACE alone. Adjusting for significant factors in univariate analysis, multivariate analysis indicated that sorafenib administration, tumor size, and alanine transaminase were independent predictors of PFS. CONCLUSION: TACE followed by sorafenib significantly improved PFS and survival in patients with advanced HCC unresponsive to TACE. |
format | Online Article Text |
id | pubmed-4621710 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-46217102015-10-30 Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis Ohki, Takamasa Sato, Koki Yamagami, Mari Ito, Daisaku Yamada, Tomoharu Kawanishi, Koki Kojima, Kentaro Seki, Michiharu Toda, Nobuo Tagawa, Kazumi Clin Drug Investig Original Research Article BACKGROUND: Sorafenib might prevent hepatocellular carcinoma (HCC) recurrence caused by the promotion of neoangiogenesis after transarterial chemoembolization (TACE). OBJECTIVES: To evaluate the efficacy and safety of TACE followed by sorafenib for treating advanced HCC. PATIENTS AND METHODS: We retrospectively analyzed 95 advanced HCC patients treated with TACE between July 2008 and December 2012 at our institution. Twenty-four patients received TACE followed by sorafenib within 14 days (S-TACE) and 71 received TACE alone. Progression-free survival (PFS) and cumulative survival from the time of non-responsiveness to TACE were compared between groups and predictive factors for PFS were analyzed. RESULTS: The median patient age was 72.2 years and 74 patients were male (77.9 %). Although median tumor size was similar between groups, the mean tumor number was significantly higher in the S-TACE versus TACE-alone group (16 vs. 8, P = 0.04). The number of prior treatments was significantly higher in the S-TACE group. Other baseline variables were similar. There were two severe adverse events in the S-TACE group and none in the TACE-alone group. Median PFS (189 vs. 106 days, P = 0.02) and median overall survival time (861 vs. 467 days, P = 0.01) from the time of non-responsiveness to TACE were significantly longer with S-TACE than TACE alone. Adjusting for significant factors in univariate analysis, multivariate analysis indicated that sorafenib administration, tumor size, and alanine transaminase were independent predictors of PFS. CONCLUSION: TACE followed by sorafenib significantly improved PFS and survival in patients with advanced HCC unresponsive to TACE. Springer International Publishing 2015-10-08 2015 /pmc/articles/PMC4621710/ /pubmed/26446004 http://dx.doi.org/10.1007/s40261-015-0333-3 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Article Ohki, Takamasa Sato, Koki Yamagami, Mari Ito, Daisaku Yamada, Tomoharu Kawanishi, Koki Kojima, Kentaro Seki, Michiharu Toda, Nobuo Tagawa, Kazumi Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis |
title | Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis |
title_full | Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis |
title_fullStr | Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis |
title_full_unstemmed | Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis |
title_short | Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis |
title_sort | efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in japan: a retrospective analysis |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621710/ https://www.ncbi.nlm.nih.gov/pubmed/26446004 http://dx.doi.org/10.1007/s40261-015-0333-3 |
work_keys_str_mv | AT ohkitakamasa efficacyoftranscatheterarterialchemoembolizationfollowedbysorafenibforintermediateadvancedhepatocellularcarcinomainpatientsinjapanaretrospectiveanalysis AT satokoki efficacyoftranscatheterarterialchemoembolizationfollowedbysorafenibforintermediateadvancedhepatocellularcarcinomainpatientsinjapanaretrospectiveanalysis AT yamagamimari efficacyoftranscatheterarterialchemoembolizationfollowedbysorafenibforintermediateadvancedhepatocellularcarcinomainpatientsinjapanaretrospectiveanalysis AT itodaisaku efficacyoftranscatheterarterialchemoembolizationfollowedbysorafenibforintermediateadvancedhepatocellularcarcinomainpatientsinjapanaretrospectiveanalysis AT yamadatomoharu efficacyoftranscatheterarterialchemoembolizationfollowedbysorafenibforintermediateadvancedhepatocellularcarcinomainpatientsinjapanaretrospectiveanalysis AT kawanishikoki efficacyoftranscatheterarterialchemoembolizationfollowedbysorafenibforintermediateadvancedhepatocellularcarcinomainpatientsinjapanaretrospectiveanalysis AT kojimakentaro efficacyoftranscatheterarterialchemoembolizationfollowedbysorafenibforintermediateadvancedhepatocellularcarcinomainpatientsinjapanaretrospectiveanalysis AT sekimichiharu efficacyoftranscatheterarterialchemoembolizationfollowedbysorafenibforintermediateadvancedhepatocellularcarcinomainpatientsinjapanaretrospectiveanalysis AT todanobuo efficacyoftranscatheterarterialchemoembolizationfollowedbysorafenibforintermediateadvancedhepatocellularcarcinomainpatientsinjapanaretrospectiveanalysis AT tagawakazumi efficacyoftranscatheterarterialchemoembolizationfollowedbysorafenibforintermediateadvancedhepatocellularcarcinomainpatientsinjapanaretrospectiveanalysis |